2-叔丁基-1H-吲哚 | 1805-65-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 2-叔丁基-1H-吲哚
• 英文名称: 2-tert-butylindole
• 英文别名: 2-(tert-butyl)-1H-indole；2-t-butylindole；2-tert-Butyl-1H-indole
• CAS: 1805-65-8
• 化学式: C₁₂H₁₅N
• mdl: MFCD04004060
• 分子量: 173.258
• InChiKey: WVPGIDWFLXGCLA-UHFFFAOYSA-N

物化性质

• 熔点：
  75-76°C
• 沸点：
  85-95 °C(Press: 0.05 Torr)
• 密度：
  1.027±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）
• 保留指数：
  2131;2131

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  应存放在2-8℃环境中，避免光照，保持干燥并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-tert-Butyl-1h-indole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-tert-Butyl-1h-indole
CAS number: 1805-65-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H15N
Molecular weight: 173.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-叔丁基-1H-吲哚 在 氧气 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 8.0h， 以58%的产率得到1-(2-aminophenyl)-2,2-dimethylpropan-1-one
  参考文献：
  名称：

  2-Arylindoles：2-氨基二苯甲酮的无过渡金属合成的新途径

  摘要：

  在O 2气球气氛下，在DMSO中由易于获得的2-芳基吲哚合成了各种2-氨基二苯甲酮。合成过程无需借助过渡金属催化剂或对湿气敏感的2-芳基吲哚有机金属试剂进行。

  DOI：

  10.1002/bkcs.10796
• 作为产物：
  描述：

  2-(3,3-二甲基丁-1-炔基)苯胺 在 silver hexafluoroantimonate 、 (1,3-bis(2,6-diisopropylphenyl)imidazolidin-2-ylidene)gold(I) chloride 、 TPGS-750-M 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.5h， 以95%的产率得到2-叔丁基-1H-吲哚
  参考文献：
  名称：

  一种对环境负责的 tezacaftor 途径，一种通过 ppm Au 催化在水中制备的用于治疗囊性纤维化的药物，作为 2-取代吲哚的入口

  摘要：

  tezacaftor 是 2018 年获批的一种药物，目前用于治疗囊性纤维化，是一种环保合成方法，该药物利用非离子表面活性剂 TPGS-750-M 在水中的化学作用进行了描述。该路线依赖于新开发的 ppm 级 Au 催化邻炔苯胺的 5 -endo-dig环化以形成所需的吲哚部分作为关键步骤。几个例子展示了这种环化的普遍性。这种方法的绿色评估是通过比较整体E因素，相对于现有的 tezacaftor 路线减少了 54%。DFT 分析合理化了胶束纳米反应器所起的重要作用，并指出了可回收催化剂在水性反应介质中的位置。

  DOI：

  10.1039/d2gc01828d
• 作为试剂：
  描述：

  4-氯亚硝基苯 在 2-叔丁基-1H-吲哚 、 氯乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以24%的产率得到
  参考文献：
  名称：

  Carloni, Patricia; Greci, Lucedio; Iacussi, Marco, Journal of Chemical Research, Miniprint, 1998, # 5, p. 1121 - 1152

  摘要：

  DOI：

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20190224188A1

  公开（公告）日：2019-07-25

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了式(I)的化合物及其药学上可接受的盐： 这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• An iron(<scp>iii</scp>)-catalyzed dehydrogenative cross-coupling reaction of indoles with benzylamines to prepare 3-aminoindole derivatives
  作者：Wei-Li Chen、Kun Li、Wei-Cong Liao、Wang-Fu Liang、Pei-Wen Qiu、Cui Liang、Gui-Fa Su、Dong-Liang Mo

  DOI：10.1039/d1gc02849a

  日期：——

  excellent yields through an iron(III)-catalyzed dehydrogenative cross-coupling reaction of 2-arylindoles and primary benzylamines under mild reaction conditions. Mechanistic studies show that a cascade reaction involves a tert-butyl nitrite (TBN)-mediated nitrosation of 2-substituted indoles and a 1,5-hydrogen shift to afford indolenine oximes, sequential iron(III)-catalyzed condensation and a 1,5-hydrogen

  我们报告了一种绿色级联方法，通过铁 ( III ) 催化的 2-芳基吲哚和伯苄胺在温和反应条件下的脱氢交叉偶联反应，以良好到优异的产率制备各种 3-氨基吲哚衍生物。机理研究表明，级联反应涉及亚硝酸叔丁酯 (TBN) 介导的 2-取代吲哚的亚硝化和 1,5-氢转移以提供吲哚啉肟、序贯铁 ( III))-催化缩合和 1,5- 氢转移在一锅反应的四个步骤中。该反应显示了吲哚和苄胺的广泛底物范围，并且可以耐受广泛的官能团。此外，反应很容易以克规模进行，反应完成后不会产生废物。3-氨基吲哚产物通过简单的萃取、洗涤和重结晶纯化，无需快速柱色谱。含有3-氨基吲哚单元的双亚胺配体易于一步获得，产率为52%。本方法突出了容易获得的起始材料、简单的纯化程序以及廉价、无毒和环境友好的铁 ( III ) 催化剂的使用。
• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Revolution Medicines, Inc.

  公开号：US20210139517A1

  公开（公告）日：2021-05-13

  The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

  本公开涉及SOS1的调节剂及其在治疗疾病中的应用。还公开了包含相同成分的药物组合物。

表征谱图